iHuman Inc.
iHuman Inc. Fundamental Analysis
iHuman Inc. (IH) shows moderate financial fundamentals with a PE ratio of 1.20, profit margin of 12.54%, and ROE of 11.04%. The company generates $0.9B in annual revenue with weak year-over-year growth of -9.42%.
Key Strengths
Areas of Concern
The stock receives a Fundamental Health Score of 40.9/100 based on profitability, valuation, growth, and balance sheet metrics. The D grade reflects weak fundamentals and significant financial concerns.
Fundamental Health Score
We analyze IH's fundamental strength across five key dimensions:
Efficiency Score
WeakIH struggles to generate sufficient returns from assets.
Valuation Score
ExcellentIH trades at attractive valuation levels.
Growth Score
WeakIH faces weak or negative growth trends.
Financial Health Score
ExcellentIH maintains a strong and stable balance sheet.
Profitability Score
WeakIH struggles to sustain strong margins.
Key Financial Metrics
Is IH Expensive or Cheap?
P/E Ratio
IH trades at 1.20 times earnings. This suggests potential undervaluation.
PEG Ratio
When adjusting for growth, IH's PEG of -0.06 indicates potential undervaluation.
Price to Book
The market values iHuman Inc. at 0.13 times its book value. This may indicate undervaluation.
EV/EBITDA
Enterprise value stands at 8.72 times EBITDA. This is generally considered low.
How Well Does IH Make Money?
Net Profit Margin
For every $100 in sales, iHuman Inc. keeps $12.54 as profit after all expenses.
Operating Margin
Core operations generate 8.56 in profit for every $100 in revenue, before interest and taxes.
ROE
Management delivers $11.04 in profit for every $100 of shareholder equity.
ROA
iHuman Inc. generates $7.77 in profit for every $100 in assets, demonstrating efficient asset deployment.
Following the Money - Real Cash Generation
Operating Cash Flow
iHuman Inc. generates limited operating cash flow of $0.00, signaling weaker underlying cash strength.
Free Cash Flow
iHuman Inc. generates weak or negative free cash flow of $0.00, restricting financial flexibility.
FCF Per Share
Each share generates $0.00 in free cash annually.
FCF Yield
IH converts 0.00% of its market value into free cash.
Financial Ratios Analysis
Valuation Ratios
P/E Ratio
Price to earnings ratio
1.20
vs 25 benchmark
PEG Ratio
Price/earnings to growth ratio
-0.06
vs 25 benchmark
P/B Ratio
Price to book value ratio
0.13
vs 25 benchmark
P/S Ratio
Price to sales ratio
0.15
vs 25 benchmark
Financial Health
Debt/Equity
Total debt to shareholders' equity
0.01
vs 25 benchmark
Current Ratio
Current assets to current liabilities
3.46
vs 25 benchmark
Efficiency Ratios
ROE
Return on equity percentage
0.11
vs 25 benchmark
ROA
Return on assets percentage
0.08
vs 25 benchmark
ROCE
Return on capital employed
0.07
vs 25 benchmark
How IH Stacks Against Its Sector Peers
| Metric | IH Value | Sector Average | Performance |
|---|---|---|---|
| P/E Ratio | 1.20 | 23.25 | Better (Cheaper) |
| ROE | 11.04% | 1240.00% | Weak |
| Net Margin | 12.54% | -9728.00% (disorted) | Strong |
| Debt/Equity | 0.01 | 0.77 | Strong (Low Leverage) |
| Current Ratio | 3.46 | 2.54 | Strong Liquidity |
| ROA | 7.77% | -203388.00% (disorted) | Weak |
IH outperforms its industry in 4 out of 6 key metrics, particularly excelling in Net Margin, but lagging in ROE.
Historical Growth Performance
5-Year Growth Trajectory
This section reviews iHuman Inc.'s 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.
Revenue CAGR
329.20%
Industry Style: Defensive, Dividend, Low Volatility
High GrowthEPS CAGR
136.40%
Industry Style: Defensive, Dividend, Low Volatility
High GrowthFCF CAGR
39.77%
Industry Style: Defensive, Dividend, Low Volatility
High Growth